BRCA2 and breast carcinoma: HRD is a pivotal biomarker in oncology, particularly for ovarian and breast cancers, expanding actionable therapeutic targets beyond BRCA1/BRCA2 mutations to enhance patient stratification for PARPi and platinum-based therapies.